Recent Progress in the Development of Opaganib for the Treatment of Covid-19

Charles D. Smith(Pennsylvania State University), Mark L. Levitt
Drug Design Development and Therapy
July 1, 2022
10.2147/dddt.s367612
Cited by 27

Related Papers

Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2
|Journal of Pharmacology and Experimental Therapeutics|2010|313
A Novel Sphingosine Kinase Inhibitor Induces Autophagy in Tumor Cells
|Journal of Pharmacology and Experimental Therapeutics|2010|111
Characterization of Isoenzyme-Selective Inhibitors of Human Sphingosine Kinases
|PLoS ONE|2012|107
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy
|International Journal of Molecular Sciences|2023|18
In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183
|Journal of Pharmacology and Experimental Therapeutics|2018|16